3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
32
Cisplatin
23
Cetuximab
14
Carboplatin
13
Magnetic Resonance Spectroscopy
12
Specimen Handling
10
Radiotherapy, Intensity-Modulated
10
Paclitaxel
9
Nivolumab
9
Docetaxel
8
Platinum
7
1,2-diaminocyclohexaneplatinum II citrate
7
Radiotherapy
5
Biopsy
5
dostarlimab
4
atezolizumab
4
Immunoglobulin G
4
Disulfides
4
Bevacizumab
4
(225)Ac-DOTA-c(RGDyK)
4
cemiplimab
3
Taxes
3
Radiation
3
Fulvestrant
3
Fluorouracil
3
budigalimab
2
amivantamab
2
abemaciclib
2
Radiotherapy, Image-Guided
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Imlunestrant
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled